title: BRD4: a BET(ter) target for the treatment of AML?
authors: Ludwig Boltzmann Cluster Oncology; Medical University of Vienna; Vienna, Austria; Department of Internal Medicine I; Division of Hematology & Hemostaseology; Medical University of Vienna; Vienna, Austria.
authors: Peter
authors: P
authors: Valent
authors: Research Institute of Molecular Pathology (IMP); Vienna, Austria.
authors: Johannes
authors: J
authors: Zuber
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001381:Azepines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D008297:Male; D058990:Molecular Targeted Therapy; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors*; D014157:Transcription Factors / Q000037:antagonists & inhibitors*; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D001381:Azepines; D009687:Nuclear Proteins; D014157:Transcription Factors; D014230:Triazoles
keywords: AML; BRD4; JQ1; leukemic stem cells; targeted therapy